Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients

Linezolid is now recommended as a first line drug for Multidrug Resistant Tuberculosis (MDR-TB). Previous studies reported hematologic toxicity as one of the main side effects. The mechanism of this toxicity is mitochondrial dysfunction, for which a biomarker is Growth differentiation factor-15 (GDF...

Descripción completa

Detalles Bibliográficos
Autores principales: Oehadian, Amaylia, Santoso, Prayudi, Menzies, Dick, Ruslami, Rovina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358446/
https://www.ncbi.nlm.nih.gov/pubmed/35957807
http://dx.doi.org/10.1016/j.idcr.2022.e01591
_version_ 1784763933011214336
author Oehadian, Amaylia
Santoso, Prayudi
Menzies, Dick
Ruslami, Rovina
author_facet Oehadian, Amaylia
Santoso, Prayudi
Menzies, Dick
Ruslami, Rovina
author_sort Oehadian, Amaylia
collection PubMed
description Linezolid is now recommended as a first line drug for Multidrug Resistant Tuberculosis (MDR-TB). Previous studies reported hematologic toxicity as one of the main side effects. The mechanism of this toxicity is mitochondrial dysfunction, for which a biomarker is Growth differentiation factor-15 (GDF-15). There is no previous report about GDF-15 and its association with hematologic toxicity from Linezolid in the treatment of MDR-TB. We present three cases of MDR-TB involving severe anemia associated with linezolid who had GDF-15 elevation. These cases highlight the need for more research into the relationship between GDF-15 and hematologic toxicity in MDR-TB patients treated with linezolid.
format Online
Article
Text
id pubmed-9358446
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93584462022-08-10 Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients Oehadian, Amaylia Santoso, Prayudi Menzies, Dick Ruslami, Rovina IDCases Case Report Linezolid is now recommended as a first line drug for Multidrug Resistant Tuberculosis (MDR-TB). Previous studies reported hematologic toxicity as one of the main side effects. The mechanism of this toxicity is mitochondrial dysfunction, for which a biomarker is Growth differentiation factor-15 (GDF-15). There is no previous report about GDF-15 and its association with hematologic toxicity from Linezolid in the treatment of MDR-TB. We present three cases of MDR-TB involving severe anemia associated with linezolid who had GDF-15 elevation. These cases highlight the need for more research into the relationship between GDF-15 and hematologic toxicity in MDR-TB patients treated with linezolid. Elsevier 2022-07-29 /pmc/articles/PMC9358446/ /pubmed/35957807 http://dx.doi.org/10.1016/j.idcr.2022.e01591 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Oehadian, Amaylia
Santoso, Prayudi
Menzies, Dick
Ruslami, Rovina
Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients
title Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients
title_full Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients
title_fullStr Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients
title_full_unstemmed Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients
title_short Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients
title_sort anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: case series of three patients
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358446/
https://www.ncbi.nlm.nih.gov/pubmed/35957807
http://dx.doi.org/10.1016/j.idcr.2022.e01591
work_keys_str_mv AT oehadianamaylia anemiawithelevationofgrowthdifferentiationfactor15levelinlinezolidtreatedmultidrugresistanttuberculosiscaseseriesofthreepatients
AT santosoprayudi anemiawithelevationofgrowthdifferentiationfactor15levelinlinezolidtreatedmultidrugresistanttuberculosiscaseseriesofthreepatients
AT menziesdick anemiawithelevationofgrowthdifferentiationfactor15levelinlinezolidtreatedmultidrugresistanttuberculosiscaseseriesofthreepatients
AT ruslamirovina anemiawithelevationofgrowthdifferentiationfactor15levelinlinezolidtreatedmultidrugresistanttuberculosiscaseseriesofthreepatients

Ejemplares similares